Viridian Therapeutics announced that enrollment is complete in THRIVE-2, its phase 3 clinical trial for VRDN-001 in patients with chronic TED.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Wedbush reveals three potential buyout targets for Biogen
- Viridian Therapeutics Releases Updated Investor Presentation
- Viridian Therapeutics’ Shareholders Approve Equity Plan Expansion
- Viridian Therapeutics updates VRDN-003 Phase 3 program in thyroid eye disease
- Viridian Therapeutics initiated with an Outperform at Wolfe Research